Selected research
Industry Research
Peptide Receptor Radionuclide Therapy (PRRT) Industry Research Report 2026
Market perspective
The global Peptide Receptor Radionuclide Therapy (PRRT) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Peptide Receptor Radionuclide Therapy (PRRT) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Peptide Receptor Radionuclide Therapy (PRRT) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Peptide Receptor Radionuclide Therapy (PRRT) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Peptide Receptor Radionuclide Therapy (PRRT) include Aurobindo Pharma, Curium Pharmaceuticals, Lantheus, Mundipharma, Bayer and Novartis, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Peptide Receptor Radionuclide Therapy (PRRT) market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Peptide Receptor Radionuclide Therapy (PRRT).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Peptide Receptor Radionuclide Therapy (PRRT) Market by Company
Aurobindo Pharma
Curium Pharmaceuticals
Lantheus
Mundipharma
Bayer
Novartis
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Type
Midgut Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor
Foregut Neuroendocrine Tumor
Hindgut Neuroendocrine Tumor
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Receptor Radionuclide Therapy (PRRT) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Receptor Radionuclide Therapy (PRRT) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Receptor Radionuclide Therapy (PRRT).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Peptide Receptor Radionuclide Therapy (PRRT) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Midgut Neuroendocrine Tumor
- Gastroenteropancreatic Neuroendocrine Tumor
- Foregut Neuroendocrine Tumor
- Hindgut Neuroendocrine Tumor
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- Aurobindo Pharma
- Curium Pharmaceuticals
- Lantheus
- Mundipharma
- Bayer
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Peptide Receptor Radionuclide Therapy (PRRT) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Midgut Neuroendocrine Tumor
- 2.2.3 Gastroenteropancreatic Neuroendocrine Tumor
- 2.2.4 Foregut Neuroendocrine Tumor
- 2.2.5 Hindgut Neuroendocrine Tumor
- 2.3 Peptide Receptor Radionuclide Therapy (PRRT) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital Pharmacies
- 2.3.3 Online Pharmacies
- 2.3.4 Retail Pharmacies
- 2.4 Assumptions and Limitations
3 Peptide Receptor Radionuclide Therapy (PRRT) Breakdown Data by Type
- 3.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Historic Market Size by Type (2021-2026)
- 3.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Forecasted Market Size by Type (2027-2032)
4 Peptide Receptor Radionuclide Therapy (PRRT) Breakdown Data by Application
- 4.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Historic Market Size by Application (2021-2026)
- 4.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Perspective (2021-2032)
- 5.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Growth Trends by Region
- 5.2.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Peptide Receptor Radionuclide Therapy (PRRT) Historic Market Size by Region (2021-2026)
- 5.2.3 Peptide Receptor Radionuclide Therapy (PRRT) Forecasted Market Size by Region (2027-2032)
- 5.3 Peptide Receptor Radionuclide Therapy (PRRT) Market Dynamics
- 5.3.1 Peptide Receptor Radionuclide Therapy (PRRT) Industry Trends
- 5.3.2 Peptide Receptor Radionuclide Therapy (PRRT) Market Drivers
- 5.3.3 Peptide Receptor Radionuclide Therapy (PRRT) Market Challenges
- 5.3.4 Peptide Receptor Radionuclide Therapy (PRRT) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Peptide Receptor Radionuclide Therapy (PRRT) Players by Revenue
- 6.1.1 Global Top Peptide Receptor Radionuclide Therapy (PRRT) Players by Revenue (2021-2026)
- 6.1.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Players (2021-2026)
- 6.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Peptide Receptor Radionuclide Therapy (PRRT) Head Office and Area Served
- 6.4 Global Peptide Receptor Radionuclide Therapy (PRRT) Players, Product Type & Application
- 6.5 Global Peptide Receptor Radionuclide Therapy (PRRT) Manufacturers Established Date
- 6.6 Global Peptide Receptor Radionuclide Therapy (PRRT) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Market Size (2021-2032)
- 7.2 North America Peptide Receptor Radionuclide Therapy (PRRT) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2021-2026)
- 7.4 North America Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Peptide Receptor Radionuclide Therapy (PRRT) Market Size (2021-2032)
- 8.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2021-2026)
- 8.4 Europe Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Market Size (2021-2032)
- 9.2 Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Peptide Receptor Radionuclide Therapy (PRRT) Market Size (2021-2032)
- 10.2 South America Peptide Receptor Radionuclide Therapy (PRRT) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2021-2026)
- 10.4 South America Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Peptide Receptor Radionuclide Therapy (PRRT) Market Size (2021-2032)
- 11.2 Middle East & Africa Peptide Receptor Radionuclide Therapy (PRRT) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Aurobindo Pharma
- 12.1.1 Aurobindo Pharma Company Information
- 12.1.2 Aurobindo Pharma Business Overview
- 12.1.3 Aurobindo Pharma Revenue in Peptide Receptor Radionuclide Therapy (PRRT) Business (2021-2026)
- 12.1.4 Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
- 12.1.5 Aurobindo Pharma Recent Developments
- 12.2 Curium Pharmaceuticals
- 12.2.1 Curium Pharmaceuticals Company Information
- 12.2.2 Curium Pharmaceuticals Business Overview
- 12.2.3 Curium Pharmaceuticals Revenue in Peptide Receptor Radionuclide Therapy (PRRT) Business (2021-2026)
- 12.2.4 Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
- 12.2.5 Curium Pharmaceuticals Recent Developments
- 12.3 Lantheus
- 12.3.1 Lantheus Company Information
- 12.3.2 Lantheus Business Overview
- 12.3.3 Lantheus Revenue in Peptide Receptor Radionuclide Therapy (PRRT) Business (2021-2026)
- 12.3.4 Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
- 12.3.5 Lantheus Recent Developments
- 12.4 Mundipharma
- 12.4.1 Mundipharma Company Information
- 12.4.2 Mundipharma Business Overview
- 12.4.3 Mundipharma Revenue in Peptide Receptor Radionuclide Therapy (PRRT) Business (2021-2026)
- 12.4.4 Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
- 12.4.5 Mundipharma Recent Developments
- 12.5 Bayer
- 12.5.1 Bayer Company Information
- 12.5.2 Bayer Business Overview
- 12.5.3 Bayer Revenue in Peptide Receptor Radionuclide Therapy (PRRT) Business (2021-2026)
- 12.5.4 Bayer Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
- 12.5.5 Bayer Recent Developments
- 12.6 Novartis
- 12.6.1 Novartis Company Information
- 12.6.2 Novartis Business Overview
- 12.6.3 Novartis Revenue in Peptide Receptor Radionuclide Therapy (PRRT) Business (2021-2026)
- 12.6.4 Novartis Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
- 12.6.5 Novartis Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst